Key Highlights
- Matinas BioPharma (NYSEAMERICAN:MTNB) reported a Q3 net loss of USD 1,765 thousand for the quarter ended Sept 30, 2026, against USD 1,532 thousand a year earlier.
- Cash and cash equivalents were USD 1,936 thousand at quarter end, down from USD 3,999 thousand at Dec 31, 2025, and the filing states substantial doubt about continuing as a going concern.
- Azurity agreed to pay up to USD 21.5 million for the unit that owns MAT2203, with USD 4.0 million due at closing and up to USD 17.5 million tied to milestones.
- Under the Business Combination Agreement with GH Power, current Matinas holders are expected to own about 9% of the combined company and GH Power holders about 91%.
MAT2203 Sale to Azurity Sets Up Cash and Milestone Terms
Matinas BioPharma (NYSEAMERICAN:MTNB) filed its Quarterly Report on Nov 16, 2026 for the period ended Sept 30, 2026. On July 10, 2026 it signed a Stock Purchase Agreement under which Azurity Pharmaceuticals will acquire all Equity interests of Nanotechnologies, the owner of MAT2203. Azurity agreed to pay cash of up to USD 21.5 million, made up of USD 4.0 million at closing, subject to downward adjustment for indebtedness, and up to USD 17.5 million on achievement of milestone events. Matinas is also eligible for a mid-single-digit Royalty on net sales and licensing proceeds from MAT2203.
GH Power Merger Would Leave Matinas Holders With About 9%
On the same day, Matinas, GH Power Inc. and several Ontario and Delaware entities signed a Business Combination Agreement. Each Matinas common share would convert into one-tenth of a Pubco common share, and the filing says that after closing the current GH Power business is expected to become the primary business. The company does not expect to continue its historical clinical-stage platform development as an independent public company. Pro forma ownership is about 9% for current Matinas equity holders and about 91% for GH Power holders, based on a valuation of USD 24.7 million for Matinas and USD 250.0 million for GH Power. Closing requires an effective Form F-4 registration statement and Ontario court orders.
Cash Falls to USD 1.9 Million While Going-Concern Doubt Remains
General and administrative expenses were USD 1,742 thousand in the quarter versus USD 1,577 thousand a year earlier, on higher legal and consulting fees. There were no Research and Development expenses in either quarter. Nine-month net loss narrowed to USD 5,012 thousand from USD 8,433 thousand. Net loss attributable to common stockholders was USD 8,886 thousand in the quarter, or USD 9.35 a share, after deemed dividends totaling USD 7,121 thousand (calculated) from down-round and inducement Warrant adjustments. Accumulated Deficit reached USD 222,920 thousand, and total Assets were USD 4,379 thousand against USD 7,208 thousand at year end.
Where Things Stand
Matinas BioPharma (NYSEAMERICAN:MTNB) is selling MAT2203 for up to USD 21.5 million because it has paused development, has little cash and is merging with GH Power, according to the filing. Management says it is focused on closing the Business Combination and the Stock Sale while conserving cash. In July 2026 the company received about USD 510 thousand net from a Series D financing of 575 Preferred Shares and about USD 2,283 thousand net from a warrant inducement at USD 5.25 a share. Nine-month operating cash outflow was USD 5,051 thousand, compared with USD 5,502 thousand a year earlier, and the filing says cash on hand is not enough to fund planned operations for twelve months from the filing date.


_11_20_2026_14_55_23_118425.jpg)



Please wait processing your request...